Using Montelukast to treat Parkinson's disease
Clinical Study to Investigate the Possible Efficacy and Safety of Montleukast in Parkinson Disease
This study is testing if Montelukast can help people with Parkinson's disease feel better while they are already taking their usual medication.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Al Mansurah) |
| Trial ID | NCT06113640 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of Montelukast, a leukotriene receptor antagonist, in patients diagnosed with Parkinson's disease who are already taking levodopa-carbidopa. The study aims to assess the potential benefits of Montelukast on both motor and non-motor symptoms associated with Parkinson's disease. By focusing on the inflammatory pathways involved in the disease, the trial seeks to explore a novel therapeutic approach that may improve patient outcomes. Participants will be monitored for changes in their symptoms and overall quality of life throughout the trial phases.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with Parkinson's disease and are currently taking levodopa.
Not a fit: Patients with atypical parkinsonian syndromes or those taking anti-inflammatory drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for managing symptoms of Parkinson's disease.
How similar studies have performed: While the use of Montelukast in Parkinson's disease is a novel approach, previous studies have explored the role of inflammatory pathways in neurodegenerative diseases, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Age ≥ 18 years Both male and female will be included Negative pregnancy test and effective contraception. Diagnosed Parkinson's disease patient taking Levodopa Exclusion Criteria: \- Secondary causes of parkinsonism Patients taking anti-inflammatory drugs Atypical parkinsonian syndromes Prior stereotaxic surgery for Parkinson's disease Pregnancy and lactation Suffering from active malignancy Addiction to alcohol and / or drugs Known allergy to the studied medications
Where this trial is running
Al Mansurah
- Faculty of Medicine, Mansoura University — Al Mansurah, Egypt (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.